GlassScriptPhysician profile
Kendra K Zuckerman
NPI 1154351294
$12,778.97
in general payments reported to CMS, 2019-2025
47 companies · $2,190 in 2025
The $2,190 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,671 · 2020: $1,088 · 2021: $1,273 · 2022: $1,702 · 2023: $2,047 · 2024: $2,808 · 2025: $2,190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,872 · Education: $173.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,872.02 |
| Education | $173.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,721.90 | 2019-2025 | Enbrel, Tavneos, Evenity |
| Abbvie INC. | $1,696.82 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $911.98 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $802.29 | 2019-2024 | Tremfya, Simponi Aria, Remicade |
| Astrazeneca Pharmaceuticals LP | $759.77 | 2021-2025 | Saphnelo |
| Novartis Pharmaceuticals Corporation | $754.71 | 2019-2025 | |
| Ani Pharmaceuticals, INC. | $679.12 | 2022-2025 | Purified Cortrophin Gel |
| Pfizer INC. | $563.12 | 2019-2025 | |
| Genentech USA, INC. | $545.23 | 2019-2025 | Actemra, Rituxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $390.14 | 2019-2024 | Cyltezo |
| E.R. Squibb & Sons, L.L.C. | $378.25 | 2019-2025 | Orencia |
| Lilly USA, LLC | $369.68 | 2019-2025 | Taltz |
| Radius Health, INC. | $349.58 | 2019-2025 | Tymlos |
| Organon LLC | $253.23 | 2021-2025 | Hadlima, Renflexis |
| Glaxosmithkline, LLC. | $245.78 | 2019-2025 | Benlysta |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendra Zuckerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.